We are international
Donate
TEXT SIZE   


ASH 2012: Dr. Richardson - A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA
12.03.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles